Aptevo Therapeutics (APVO)
Developer of multispecific cancer immunotherapies and radiopharmaceutical oncology programs.
Something off on this page? Send us feedback.
Develops multispecific immunotherapy candidates for blood and solid-tumor cancers and is expanding into radiopharmaceutical oncology with Niowave. Operates through program development and collaboration rather than documented commercial product sales, using the ADAPTIR and ADAPTIR-FLEX platforms.
Develops multispecific cancer immunotherapies through the ADAPTIR and ADAPTIR-FLEX protein-engineering platforms. The Seattle-based clinical-stage company uses bispecific and trispecific molecules designed to engage multiple biological targets across blood and solid-tumor malignancies. Mipletamig is the named clinical candidate, alongside additional preclinical assets.
Extends that platform into radiopharmaceutical oncology through a collaboration with Niowave, pairing tumor-targeting molecules with isotope manufacturing and supply capabilities. The portfolio contains development candidates rather than marketed medicines, making clinical results, regulatory progress, and partner execution central to its operating model. The radiopharmaceutical effort depends on Niowave's isotope infrastructure.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.8M · Total debt $4.2M · Total assets $14.5M · Shareholders' equity $6.0M
- Revenue
- $0
- Operating income
- −$6.4M
- Net income
- −$6.4M
No dividends on record.
| Institutions9 holders · as of Mar 31, 2026 | 4.31% | 53.8K shares | |
| Insiders10 holders · as of Aug 10, 2026 | 0.54% | 6.7K shares | |
| Strategic holders2 holders · as of Jun 22, 2026 | 12.18% | 151.7K shares | |
| Otherremainder | 82.97% | 1.03M shares |
1.25M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (1.80M in the company's Sep 3, 2026 report, 1.25M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Niowave, Inc.1Strategic10 percent owner | 12.18% | 151,723 | 13Gfiled Jun 22, 2026 ↗ |
Gsa Capital Partners LLPInstitution | 1.58% | 19,638 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 1.07% | 13,337 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 1.02% | 12,713 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.33% | 4,142 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Niowave, Inc.'s transaction reports restate only vehicles that traded; the 2026 ownership statement (151.7K) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 10, 2025 | Grady III Grant | director | +13,513 | $1.49 |
- Regeneron
Blood-cancer CD3 bispecifics target the same immune-engager field.
- Amgen
BiTE therapies span the same blood and solid-tumor immune-engager field.
- Genmab (ADR)
CD3 bispecifics in B-cell cancers share the hematologic-oncology field.
- Janux Therapeutics
Solid-tumor T-cell engagers challenge the same clinical-development field.
- Xencor
Bispecific-antibody platforms overlap in oncology development and partnering.
- Novartis (ADR)
Targeted radioligand therapies overlap with the new oncology expansion.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aptevo Therapeutics | $2.28 | −12.98% | $5.7M | — | — | — | — |
| Regeneron | $850.48 | −0.18% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Amgen | $442.50 | −0.08% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Genmab (ADR) | $34.40 | +0.55% | $21.01B | 27.0 | 26.6 | 2.1 | +24.9% |
| Janux Therapeutics | $19.61 | −0.36% | $1.20B | — | — | 37.7 | — |
| Xencor | $27.00 | +0.37% | $1.99B | — | — | 19.0 | +17.5% |
| Novartis (ADR) | $162.04 | −0.25% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 25.7 | 18.1 | 6.0 | +16.7% |